U.S. Markets closed

Biogen Inc. (BIIB)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
274.64+3.39 (+1.25%)
At close: 4:00PM EDT

274.69 0.05 (0.02%)
After hours: 4:43PM EDT

People also watch
CELGREGNGILDAMGNALXN
Full screen
Previous Close271.25
Open271.25
Bid263.00 x 200
Ask279.00 x 200
Day's Range269.09 - 275.51
52 Week Range232.00 - 333.65
Volume1,083,834
Avg. Volume1,619,750
Market Cap58.67B
Beta0.45
PE Ratio (TTM)17.20
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Market Realist1 hour ago

    How Biogen’s Tecfidera Is Expected to Perform in 2017

    In 2016, Biogen’s (BIIB) Tecfidera reported revenues of ~$4.0 billion, which reflected ~9% growth year-over-year (or YoY).

  • Market Realist3 hours ago

    What’s in Biogen’s Clinical Pipeline?

    Currently, Biogen is conducting 13 clinical studies in early phases and expects promising results from those trials.

  • American City Business Journals10 hours ago

    Like Biogen, this Fidelity-backed startup is targeting a deadly infant disease

    Since being launched in 2014 with financing from Fidelity and other prominent investors, Cambridge-based Scholar Rock has been developing a drug that is designed to block a protein that limits muscle growth. On Wednesday, the privately-held, 40-employee company revealed for the first time which disease it plans to target: spinal muscular atrophy, or SMA, a leading genetic cause of death in infants. There was no approved treatment for SMA until December 2016, when the FDA green-lighted Biogen's (BIIB) Spinraza.